Pharvaris (NASDAQ:PHVS) PT Raised to $42.00

Pharvaris (NASDAQ:PHVS) had its price objective increased by Oppenheimer from $38.00 to $42.00 in a research note published on Friday morning, Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

Separately, Wedbush decreased their price objective on shares of Pharvaris from $35.00 to $31.00 and set an outperform rating for the company in a report on Thursday, May 9th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and a consensus price target of $33.60.

Pharvaris Trading Up 3.8 %

Shares of PHVS stock opened at $19.85 on Friday. The firm has a 50-day moving average of $17.75 and a 200-day moving average of $20.13. Pharvaris has a one year low of $15.00 and a one year high of $33.00.

Pharvaris (NASDAQ:PHVS) last announced its earnings results on Wednesday, August 14th. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.02). On average, sell-side analysts forecast that Pharvaris will post -2.58 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Blackstone Inc. bought a new stake in shares of Pharvaris during the 4th quarter worth $2,805,000. Commodore Capital LP bought a new stake in shares of Pharvaris in the 4th quarter worth approximately $22,440,000. venBio Partners LLC raised its holdings in Pharvaris by 15.4% in the 4th quarter. venBio Partners LLC now owns 4,919,504 shares of the company’s stock worth $137,992,000 after purchasing an additional 654,832 shares in the last quarter. Novo Holdings A S lifted its position in shares of Pharvaris by 47.7% in the 2nd quarter. Novo Holdings A S now owns 1,725,000 shares of the company’s stock worth $32,430,000 after purchasing an additional 556,970 shares during the period. Finally, Deerfield Management Company L.P. Series C boosted its position in shares of Pharvaris by 31.6% during the second quarter. Deerfield Management Company L.P. Series C now owns 1,397,279 shares of the company’s stock valued at $26,269,000 after purchasing an additional 335,687 shares in the last quarter.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.